Teligent launches Cefotan

BUENA, N.J.  — Generic specialty pharmacy company Teligent announced the launch of its Cefotan (cefotetan for injection) on Monday. The drug launch marks the first product Teligent is rolling out from its portfolio of withdrawn and discontinued drug applications that the company acquired from AstraZeneca in 2014. 

 

“With the launch of Cefotan, we are now marketing four injectable products in the US, and nineteen in Canada,” Teligent president and CEO Jason Grenfell-Gardner said. “This is our first product launch that will start to address the drug shortage concerns in the United States.”

 

The drug is indicated to treat bacterial infections or prevent bacterial infections following certain surgeries.